Boluwatife OLU Afolabi

Nigeria’s HPV Vaccine Moment

The HPV vaccine is a scientific miracle

Very few tools in modern medicine are as quietly revolutionary as the HPV vaccine. It can prevent an entire family of cancers [cervical, anal, genital and a large share of oropharyngeal tumours] by blocking the high‑risk HPV types that cause them.

Large trials and real‑world studies show that girls vaccinated before age 16 are about 80% less likely to develop cervical cancer than their unvaccinated peers, and that vaccination cuts oral HPV16/18 infections by roughly 90%. Emerging evidence and modelling suggest that men who receive HPV vaccination have far fewer HPV‑related head and neck cancers later in life.

Across the world, the old map of head and neck squamous cell carcinoma is being redrawn. As tobacco and alcohol‑driven tumors slowly decline, HPV‑positive cancers of the oropharynx and related sites are rising, especially in high‑income countries. These newer cancers tend to affect people in their 40s and 50s, often with little or no smoking history, and in some series now make up most oropharyngeal cancers.

Nigeria has a fragile success story

Nigeria introduced a single‑dose HPV vaccine into the national immunisation schedule in October 2023, beginning with a campaign that aimed to reach 7.7 million girls aged 9–14 years in 16 states. Government and partner reports suggest that within the first phase of this roll‑out, roughly  70% of girls in this age group [about 12 million] have received a dose so far. If that level of uptake can be maintained and expanded, modelling suggests it could eventually prevent up to 10,000 new cervical cancer cases and 7,000 deaths every year.

Yet, this success story is not exactly what it seems. A closer look shows how uneven it is. A 2024 survey in Abuja, Nasarawa and Adamawa found uptake as high as 67% in Nasarawa but just 28% in Adamawa, and many caregivers were still unclear about the recommended age window and schedule. Additionally, these numbers sit against a very harsh backdrop. In 2020, Nigeria recorded about 12,000 new cervical cancer cases and 8,000 deaths, making it the second leading cause of cancer death in women aged 15–44. Because cervical and many HPV‑related head and neck cancers take decades to appear, the girls in our classrooms today are the women and men who will fill [or empty] our oncology clinics in the 2040s and 2050s.

The single‑dose strategy, supported by recent African trials showing around 97% protection against persistent vaccine‑type HPV infection and strong modelling of cost‑effectiveness, gives Nigeria a realistic path to scale. But that promise depends on two things:

The danger of conspiracies

At this point, I'd like to remind you that the real threat to that future is not only the national assembly budget lines or cold‑chain failures due to our perpetual lack of electricity, but stories and conspiracies that become much more amplified on social media [and have slowly changed the perception of Nigerians towards vaccines and vaccination] that the HPV vaccine is a secret tool to sterilize Nigerian girls, to "depopulate" Africa, to experiment on Black bodies at the behest of some distant billionaires.

These narratives draw on older wounds like the 2003 polio vaccine boycott in northern Nigeria, which was fueled by allegations of hidden anti‑fertility agents and contamination, triggered a sharp resurgence of polio in Nigeria and helped seed outbreaks across three continents.

Today, rapidly spreading online campaigns and some local influencers [on Twitter/X, WhatsApp, Facebook, Instagram etc] recycle similar claims against HPV vaccination, often naming Bill Gates as a symbol of foreign control. Independent investigations and global health agencies have repeatedly examined these allegations and found no evidence that his foundation’s vaccine work has caused mass infertility or deliberate harm. Yet in the attention economy, the correction never travels as far as the original lie.

These conspiracy theories are particularly dangerous because are stitched from real histories of medical abuse, structural inequality and geopolitical humiliation, then amplified by social media algorithms that reward outrage and conspiracy. If the public health experts only respond with technical facts and glossy posters, without addressing the politics of trust and the memory of past harms, the result will be predictable: lower HPV vaccine uptake and more preventable cancers.

What Nigeria must do next

In very simple terms, Nigeria’s task is to “roll out a vaccine” and to build a social contract around it simultaneously: one dose in the arm, and one honest conversation in the community. That means funding long‑term engagement with religious and traditional leaders, teachers, women’s groups and youth influencers, not as afterthoughts, but as co‑designers of the programme. They need clear, culturally grounded explanations of what HPV is, how it causes both cervical and throat cancers, and why vaccination before sexual debut matters.

It also means stepping into the online spaces where misinformation thrives. Health authorities and civil society should partner with Nigerian content creators and survivors of cervical and head and neck cancers to tell more persuasive, more truthful stories than the conspiracies that currently dominate too many timelines.

Our law-makers and policy‑makers can lock in the gains of the current campaign by guaranteeing recurrent funding for single‑dose HPV vaccination of all girls aged 9–14, and by piloting school‑based delivery in every state. They should also plan now for a phased shift to gender‑neutral vaccination as budgets and supply allow, because the evidence for protecting boys against oral HPV and oropharyngeal cancers is growing.

At the same time, Nigeria must strengthen screening and early detection for cervical cancer, so that the generations who missed vaccination are not abandoned while we wait for vaccine benefits to mature. If the country can hold its nerve against misinformation, use its one‑dose strategy to close equity gaps between states, and treat community trust as core infrastructure rather than "soft work", I believe it can bend the future curve of both cervical cancer and HPV‑related head and neck cancers, and spare hundreds of thousands of young Nigerians from learning the vocabulary of oncology the hard way.

-Boluwatife OLU Afolabi